SMMT SUMMIT THERAPEUTICS INC Product Launches 8-K Filing 2024 - Product Launch Summit Therapeutics Inc. announced that Monotherapy Ivonescimab achieved clinically meaningful progression-free survival (PFS) benefit in a Phase III clinical trial conducted in China.Get access to all SEC 8-K filings of the SUMMIT THERAPEUTICS INC